These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 25795148)

  • 1. Proteomics applications in prion biology and structure.
    Moore RA; Faris R; Priola SA
    Expert Rev Proteomics; 2015 Apr; 12(2):171-84. PubMed ID: 25795148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomic analysis of prion diseases: creating clarity or causing confusion?
    Rubenstein R
    Electrophoresis; 2012 Dec; 33(24):3631-43. PubMed ID: 23161058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein Misfolding Cyclic Amplification of Infectious Prions.
    Moda F
    Prog Mol Biol Transl Sci; 2017; 150():361-374. PubMed ID: 28838669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conformational conversion of prion protein in prion diseases.
    Zhou Z; Xiao G
    Acta Biochim Biophys Sin (Shanghai); 2013 Jun; 45(6):465-76. PubMed ID: 23580591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic prions and other human neurodegenerative proteinopathies.
    Le NT; Narkiewicz J; Aulić S; Salzano G; Tran HT; Scaini D; Moda F; Giachin G; Legname G
    Virus Res; 2015 Sep; 207():25-37. PubMed ID: 25449570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration.
    Costanzo M; Zurzolo C
    Biochem J; 2013 May; 452(1):1-17. PubMed ID: 23614720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unraveling the details of prion (con)formation(s): recent advances by mass spectrometry.
    Principe S; Maras B; Schininà ME; Pocchiari M; Cardone F
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):697-707. PubMed ID: 18729021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Searching for reliable premortem protein biomarkers for prion diseases: progress and challenges to date.
    Ma D; Li L
    Expert Rev Proteomics; 2012 Jun; 9(3):267-80. PubMed ID: 22809206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of "omics" to prion biomarker discovery.
    Huzarewich RL; Siemens CG; Booth SA
    J Biomed Biotechnol; 2010; 2010():613504. PubMed ID: 20224650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of proteomics in understanding prion infection.
    Campisi E; Cardone F; Graziano S; Galeno R; Pocchiari M
    Expert Rev Proteomics; 2012 Dec; 9(6):649-66. PubMed ID: 23256675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of the real-time quaking-induced conversion assay in diagnosis, prion strain-typing, drug pre-screening and other amyloidopathies.
    Candelise N; Schmitz M; Da Silva Correia SM; Arora AS; Villar-Piqué A; Zafar S; Llorens F; Cramm M; Zerr I
    Expert Rev Mol Diagn; 2017 Oct; 17(10):897-904. PubMed ID: 28817974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prion protein and metal interaction: physiological and pathological implications.
    Singh N; Das D; Singh A; Mohan ML
    Curr Issues Mol Biol; 2010; 12(2):99-107. PubMed ID: 19767653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Capillary electromigration based techniques in diagnostics of prion protein caused diseases.
    Sobrova P; Ryvolova M; Adam V; Kizek R
    Electrophoresis; 2012 Dec; 33(24):3644-52. PubMed ID: 23161211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomics analysis of amyloid and nonamyloid prion disease phenotypes reveals both common and divergent mechanisms of neuropathogenesis.
    Moore RA; Sturdevant DE; Chesebro B; Priola SA
    J Proteome Res; 2014 Nov; 13(11):4620-34. PubMed ID: 25140793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the natural variability of prion diseases.
    Geissen M; Krasemann S; Matschke J; Glatzel M
    Vaccine; 2007 Jul; 25(30):5631-6. PubMed ID: 17391814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental approaches to the interaction of the prion protein with nucleic acids and glycosaminoglycans: Modulators of the pathogenic conversion.
    Silva JL; Vieira TC; Gomes MP; Rangel LP; Scapin SM; Cordeiro Y
    Methods; 2011 Mar; 53(3):306-17. PubMed ID: 21145399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prion protein self-interactions: a gateway to novel therapeutic strategies?
    Rigter A; Langeveld JP; van Zijderveld FG; Bossers A
    Vaccine; 2010 Nov; 28(49):7810-23. PubMed ID: 20932496
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prions and their biology].
    Gasset M; Westaway D
    Rev Neurol; 2000 Jul 16-31; 31(2):129-32. PubMed ID: 10951668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Unexposed Secrets of Prion Protein Oligomers.
    Wang G; Wang M; Li C
    J Mol Neurosci; 2015 Aug; 56(4):932-937. PubMed ID: 25823438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathogenic mechanisms of prion diseases.
    Unterberger U; Voigtländer T
    CNS Neurol Disord Drug Targets; 2007 Dec; 6(6):424-55. PubMed ID: 18220781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.